Top Story

FDA advisory committee supports insulin degludec/liraglutide for type 2 diabetes

May 24, 2016

An FDA advisory panel unanimously recommended approval for a fixed combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.

The Endocrinologic and Metabolic Drugs Advisory Committee voted 16-0 Tuesday in favor of a new drug application for insulin degludec and liraglutide (IDegLira), a fixed-ratio combination of a glucagon-like peptide-1 receptor agonist and a basal insulin. Insulin degludec (Tresiba) and liraglutide (Victoza) are both approved agents; the drug combination is developed by Novo Nordisk.

Meeting News Coverage

AACE celebrates 25 years with latest research at annual meeting

May 24, 2016
The American Association of Clinical Endocrinologist’s annual meeting will go “back to the future” as it celebrates its silver anniversary this year…
FDA News

FDA expands indication for Invokamet

May 24, 2016
The FDA today approved Janssen’s Invokamet as a first-line treatment in adults with type 2 diabetes, according to a company press release. Invokamet is a…
Meeting News Coverage

Balloon capsules, swallowed then inflated, produce weight loss in nearly 65%

May 24, 2016
SAN DIEGO — Nearly 65% of participants who swallowed three capsules then filled with gas lost 5% or more of their total body weight, according to a presentation at…
In the Journals

Flame-retardant exposure increases thyroid disease risk in women

May 24, 2016
High blood levels of polybrominated diphenyl ethers, or PBDEs, a common type of flame retardant, may increase the risk for thyroid problems in women, with the effect…
More News Headlines »

Obesity Consults® ObesityForum® 2015 Highlights

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Novo Nordisk, Inc.

Obesity has increased dramatically in the past 20 years and is considered a health care epidemic in the United States…
More »
Meeting News Coverage

VIDEO: Breaks in sitting time reduce cardiometabolic risk factors in type 2 diabetes

May 4, 2016
More »
Highlights from ENDO 2016

Highlights from ENDO 2016


The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Recent processes have been established to facilitate the production, validation, and utilization of biosimilars…
More »
Current Issues
View the Current Issues